ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
CRO consolidation continues as ICON splashes $12B for PRA Health Sciences
ICON has agreed to acquire PRA Health Sciences to broaden its abillity to provide decentralised and hybrid trial solutions.
COVID researchers ICON, PRA Health join in $12 billion deal
ICON agreed to buy PRA Health Sciences Inc. in a $12 billion cash and stock deal that combines two research providers supporting Covid vaccine and treatment trials.
ICON eyes growing virtual clinical trial market with $12 billion PRA Health deal
ICON will buy rival PRA Health Sciences Inc in a deal valued at about $12 billion, to create a contract drug research firm that can tap into the growing demand for virtual clinical trials due to the pandemic.
ICON to buy clinical trial rival PRA in $12 billion deal
In acquiring PRA, ICON would expand into digital and technology capabilities that are playing roles in clinical trials accelerated by the Covid-19 pandemic, such as virtual monitoring of study subjects as people stay at home and avoid public places.
In the biggest CRO takeover in years, ICON doles out $12B for PRA Health Sciences to focus on decentralised clinical work
ICON will acquire PRA Health Sciences for $12 billion in a move that will shake up the hightest rungs of a fragmented market.
Dublin clinical trials group ICON buys PRA in $12bn deal
The combined company will form the world’s largest contract research organisation, and is to be headquartered at ICON’s Leopardstown campus in Dublin.
Deal watch: ICON, PRA Health form massive CRO In $12bn merger
ICON acquires PRA Health Sciences to form a world-leader CRO.
ICON eyes growing virtual clinical trial market with $12 bln PRA Health deal
An article reporting on ICON's acquisition of contract research organisation PRA Health Sciences
COVID trials vaccine firm ICON announces €10bn US takeover deal
ICON has announced one of the biggest takeover deals in Irish corporate history.
ICON to buy contract researcher PRA Health for $12B
ICON will buy PRA Health Sciences for about $12 billion in cash and stock, snapping up one of the larger independent companies in the drugmaker services business.